HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers.
Saved in:
| Title: | HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers. |
|---|---|
| Authors: | El-Botty R; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Vacher S; Department of Genetics, Institut Curie, PSL Research University, Paris, France., Mainguené J; Department of Genetics, Institut Curie, PSL Research University, Paris, France.; Medical Oncology Department, Institut Curie, PSL Research University, Paris, France., Briaux A; Department of Genetics, Institut Curie, PSL Research University, Paris, France., Ibadioune S; Department of Genetics, Institut Curie, PSL Research University, Paris, France., Dahmani A; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Montaudon E; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Nemati F; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Huguet L; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Sourd L; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Morriset L; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Château-Joubert S; BioPole Alfort, Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, France., Dubois T; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Maire V; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Lidereau R; Department of Genetics, Institut Curie, PSL Research University, Paris, France., Rapinat A; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Gentien D; Translational Research Department, Institut Curie, PSL Research University, Paris, France., Coussy F; Department of Genetics, Institut Curie, PSL Research University, Paris, France.; Medical Oncology Department, Institut Curie, PSL Research University, Paris, France., Bièche I; Department of Genetics, Institut Curie, PSL Research University, Paris, France.; Faculty of Pharmaceutical and Biological Sciences, Paris City University, Inserm U1016, France., Marangoni E; Translational Research Department, Institut Curie, PSL Research University, Paris, France. |
| Source: | Molecular oncology [Mol Oncol] 2023 Oct; Vol. 17 (10), pp. 2017-2028. Date of Electronic Publication: 2023 Mar 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.13412 |
